最新ニュース Veru (NASDAQ:VERU) 株価情報

Veru

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

Veru Inc

VERUS INTL INC by Verus International, Inc.

Verus International Inc

VerusCoin

<p>Rogers Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCI#NYSE">RCI</a>) reported quarterly earnings of C$1.46 per share which beat the analyst consensus estimate of C$1.36 by 7.35 percent. This is a 22.69 percent increase over earnings of C$1.19 per share from the same period last year. The company reported quarterly sales of C$5.480 billion which beat the analyst consensus estimate of C$5.392 billion by 1.63 percent. This is a 2.72 percent increase over sales of C$5.335 billion the same period last year.</p>


Earnings

Earnings Beats

News

CORRECTION: Rogers Communications Q4 2024 Adj. EPS C$1.46 Beats C$1.36 Estimate, Sales C$5.480B Beat C$5.392B Estimate

<p><strong>Exxon Mobil Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) will be reporting its fourth-quarter earnings on Friday. Wall Street expects $1.56 in EPS and $86.63 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=XOM" target="_blank" rel="noreferrer noopener"> before market hours</a>.</p>
<p>The stock is up 3.98% over the past year, 1.59% YTD.</p>
<p>Let&#8217;s look at what the charts indicate for Exxon Mobil stock and how the stock currently maps against Wall Street estimates.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/25/01/42922934/oil-stocks-rally-on-anticipation-of-stricter-russian-sanctions-heres-how-etfs-are-reacting">Oil Stocks Rally On Anticipation Of Stricter Russian Sanctions: Here&#8217;s How ETFs Are Reacting</a></strong></p>
<h1 class="wp-block-heading"><strong>Exxon Mobil Stock Strongly Bearish Ahead Of Q4 Earnings </strong></h1>
<p>Exxon Mobil stock is in a strongly bearish trend, with its share price below the five-, 20- and 50-day exponential moving averages.</p>
<p><figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent013025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="626" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30125525/Screenshot-2025-01-30-at-11.24.56-PM.png" alt="" class="wp-image-758672" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30125525/Screenshot-2025-01-30-at-11.24.56-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30125525/Screenshot-2025-01-30-at-11.24.56-PM-300x235.png 300w" sizes="(max-width: 626px) 100vw, 626px" /></a></figure></p>
<p><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent013025&amp;t=be2bearmibe3na1"><em>Chart created using Benzinga Pro</em></a></p>
<p>Exxon Mobil stock is also trading below key simple moving averages, including the eight-day ($109.47), 20-day ($109.13), 50-day ($111.65) and 200-day ($115.42), reinforcing bearish sentiment.</p>
<p>Additionally, the MACD indicator at a negative 0.38 signals continued downside momentum, while the RSI at 47.38 suggests Exxon Mobil stock is approaching oversold territory but has yet to reach a reversal zone.</p>
<p>Despite the bearish technical setup, underlying buying pressure hints at a potential shift toward bullish movement. Investors should monitor for a breakout above short-term resistance levels, which could signal a trend reversal.</p>
<h1 class="wp-block-heading"><strong>Exxon Mobil Analysts See 13.5% Upside</strong></h1>
<p><strong>Ratings &amp; Consensus Estimates:</strong><a href="https://www.benzinga.com/quote/XOM/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Exxon Mobil stock stands at a Buy currently with a price target of $128.04. The latest analyst ratings from Truist, Piper Sandler and JPMorgan imply a 13.5% upside for XOM stock.</p>
<p><strong>XOM</strong> <strong>Price Action: </strong>Exxon Mobil stock was trading up by 0.82% at $109.54 at the time of publication Thursday</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43200965/goldman-sachs-stays-on-the-sidelines-on-exxon-mobil-heres-why">Goldman Sachs Stays On The Sidelines On Exxon Mobil &#8211; Here&#8217;s Why</a></strong></li>
</ul>
<p><em>Photo: Del Henderson Jr. via Shutterstock</em></p>


Technicals

Commodities

Previews

Tech

Trading Ideas

Exxon Mobil Stock Faces Resistance: Can Q4 Earnings Spark A Reversal?

<p><strong>Brunswick Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BC#NYSE">BC</a>) reported fourth-quarter financial results before the market open on Thursday. Here&#8217;s a <a href="https://www.benzinga.com/pressreleases/25/01/g43330764/brunswick-corporation-releases-2024-fourth-quarter-full-year-earnings">rundown of the report</a>.</p>
<ul>
<li><strong>Q4 Revenue: </strong>$1.154 billion, versus estimates of $1.051 billion</li>
</ul>
<ul>
<li><strong>Q4 Adjusted EPS: </strong>24 cents, versus estimates of 21 cents</li>
</ul>
<p>Brunswick ended the quarter with $286.7 million in cash and marketable securities, down $193 million from the end of 2023.</p>
<p>&#8220;We had a very solid finish to 2024 characterized by significant cash generation in the fourth quarter, further outboard engine market share gains, successful new product launches, and optimal operating performance in the circumstances, all of which enabled us to conclude full-year 2024 slightly ahead of our recent expectations,&#8221; said <strong>David Foulkes</strong>, CEO of Brunswick.</p>
<p><strong>Outlook:</strong> Brunswick expects first-quarter revenue to be between $1 billion and $1.2 billion versus estimates of $1.27 billion. The marine recreation company expects first-quarter adjusted earnings to be between 15 cents and 25 cents per share versus estimates of $1.08 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p>Brunswick sees full-year 2025 revenue in the range of $5.2 billion to $5.6 billion versus estimates of $5.28 billion. The company expects full-year 2025 adjusted earnings of $3.50 to $5.0 per share versus estimates of $5.14 per share.</p>
<p>&#8220;2025 has the potential to be a year of steadily easing financial conditions, and while we enter the year with a cautious outlook, particularly for the first quarter, we have already launched many new products across our businesses and we remain extremely focused on delivering steady free cash flow and resilient EPS, and driving continued strong shareholder returns,&#8221; the company said.</p>
<p><strong>BC Price Action:</strong> <a href="http://benzinga.com/quote/bc">Brunswick shares</a> were up 3.29% at $70.31 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/general/gaming/25/01/43342224/ryan-cohen-moves-gamestop-shares-to-personal-name-sparking-speculation-on-next-steps"><strong>Ryan Cohen Moves 36.8 Million GameStop Shares To Personal Name, Sparking Speculation On Next Steps</strong></a></li>
</ul>
<p><em>This illustration was generated using artificial intelligence via Midjourney.</em></p>


Guidance

Movers

Brunswick Q4 Earnings: Revenue Beat, EPS Beat, 'Cautious' Q1 Outlook And More

<p>5 analysts have expressed a variety of opinions on Applied Industrial Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $297.0, a high estimate of $325.00, and a low estimate of $265.00. This current average has increased by 12.5% from the previous average price target of $264.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738263685_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Applied Industrial Techs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Manthey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$275.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Sam Darkatsh</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Ken Newman</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$325.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Sabrina Abrams</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$315.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Christopher Glynn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$305.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Applied Industrial Techs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Applied Industrial Techs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Applied Industrial Techs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Applied Industrial Techs's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AIT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Applied Industrial Techs analyst ratings.</strong></a></p>
<h2>Discovering Applied Industrial Techs: A Closer Look</h2>
<p>Applied Industrial Technologies Inc is a distributor of industrial products to the maintenance, repair, and operations market and the original equipment manufacturing industry. Further, the company provides engineering and design services for industrial and fluid power applications. The products include bearings, power transmission components, fluid power components and systems, industrial rubber products, linear motion components, safety products, oilfield supplies, and other industrial and maintenance supplies. The company's reportable segments are; Service Center Based Distribution which derives key revenue, and Engineered Solutions. Geographically, the company derives its key revenue from the United States and the rest from Canada and other countries.</p>
<h3>Unraveling the Financial Story of Applied Industrial Techs</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Applied Industrial Techs showcased positive performance, achieving a revenue growth rate of <strong>0.34%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Applied Industrial Techs's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>8.38%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>5.35%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Applied Industrial Techs's ROA excels beyond industry benchmarks, reaching <strong>3.09%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Applied Industrial Techs's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.34</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Applied Industrial Techs Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

<p>Financial giants have made a conspicuous bullish move on Broadcom. Our analysis of options history for Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) revealed 162 unusual trades.</p>
<p>Delving into the details, we found 58% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 48 were puts, with a value of $2,949,647, and 114 were calls, valued at $7,145,899.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $155.0 to $370.0 for Broadcom during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Broadcom's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Broadcom's whale trades within a strike price range from $155.0 to $370.0 in the last 30 days. </p>
<h3>Broadcom Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738263684_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AVGO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$44.95</td>
<td>$44.4</td>
<td>$44.45</td>
<td>$240.00</td>
<td>$280.0K</td>
<td>1.2K</td>
<td>521</td>
</tr>
<tr>
<td>AVGO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$47.95</td>
<td>$47.35</td>
<td>$47.95</td>
<td>$200.00</td>
<td>$239.7K</td>
<td>2.2K</td>
<td>58</td>
</tr>
<tr>
<td>AVGO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$5.7</td>
<td>$5.55</td>
<td>$5.7</td>
<td>$230.00</td>
<td>$228.0K</td>
<td>7.1K</td>
<td>2.9K</td>
</tr>
<tr>
<td>AVGO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$1.1</td>
<td>$1.04</td>
<td>$1.09</td>
<td>$190.00</td>
<td>$179.8K</td>
<td>4.1K</td>
<td>1.8K</td>
</tr>
<tr>
<td>AVGO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$26.85</td>
<td>$26.8</td>
<td>$26.8</td>
<td>$215.00</td>
<td>$134.0K</td>
<td>1.0K</td>
<td>307</td>
</tr>
</tbody>
</table>
</p>
<h3>About Broadcom</h3>
<p>Broadcom is the sixth-largest semiconductor company globally and has expanded into various software businesses, with over $30 billion in annual revenue. It sells 17 core semiconductor product lines across wireless, networking, broadband, storage, and industrial markets. It is primarily a fabless designer but holds some manufacturing in-house, like for its best-of-breed FBAR filters that sell into the Apple iPhone. In software, it sells virtualization, infrastructure, and security software to large enterprises, financial institutions, and governments.Broadcom is the product of consolidation. Its businesses are an amalgamation of former companies like legacy Broadcom and Avago Technologies in chips, as well as Brocade, CA Technologies, and Symantec in software.</p>
<p>Having examined the options trading patterns of Broadcom, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Broadcom Standing Right Now?</h3>
<ul>
<li>With a volume of 28,803,641, the price of AVGO is up 4.73% at $216.1. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 35 days.</li>
</ul>
<h3>What Analysts Are Saying About Broadcom</h3>
<p>Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $255.33333333333334.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Broadcom with a target price of $246.<br />
&#x2A; Consistent in their evaluation, an analyst from Mizuho keeps a Outperform rating on Broadcom with a target price of $260.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Broadcom with a target price of $260. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Broadcom with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

AVGO

Behind the Scenes of Broadcom's Latest Options Trends

<p>Deep-pocketed investors have adopted a bullish approach towards Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CMCSA usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 32 extraordinary options activities for Comcast. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 71% leaning bullish and 15% bearish. Among these notable options, 19 are puts, totaling $1,416,299, and 13 are calls, amounting to $590,967.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $50.0 for Comcast over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Comcast's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Comcast's significant trades, within a strike price range of $30.0 to $50.0, over the past month.</p>
<h3>Comcast Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738263679_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CMCSA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$3.05</td>
<td>$2.94</td>
<td>$2.99</td>
<td>$30.00</td>
<td>$448.5K</td>
<td>55</td>
<td>1.5K</td>
</tr>
<tr>
<td>CMCSA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.05</td>
<td>$4.85</td>
<td>$5.0</td>
<td>$30.00</td>
<td>$125.0K</td>
<td>98</td>
<td>273</td>
</tr>
<tr>
<td>CMCSA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$7.75</td>
<td>$6.3</td>
<td>$6.25</td>
<td>$40.00</td>
<td>$125.0K</td>
<td>2.4K</td>
<td>200</td>
</tr>
<tr>
<td>CMCSA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.15</td>
<td>$3.1</td>
<td>$3.1</td>
<td>$37.50</td>
<td>$110.7K</td>
<td>5.5K</td>
<td>406</td>
</tr>
<tr>
<td>CMCSA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$4.45</td>
<td>$4.35</td>
<td>$4.35</td>
<td>$37.00</td>
<td>$87.0K</td>
<td>5.7K</td>
<td>1.5K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Comcast</h3>
<p>Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to 63 million US homes and businesses, or nearly half of the country. About 50% of the locations in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC network, the Peacock streaming platform, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is a large television provider in the UK and has invested heavily in proprietary content to build this position. Sky is also a large pay-television provider in Italy and has a presence in Germany and Austria.</p>
<p>After a thorough review of the options trading surrounding Comcast, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Comcast's Current Market Status</h3>
<ul>
<li>With a trading volume of 47,282,864, the price of CMCSA is down by -12.07%, reaching $32.85.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 0 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Comcast</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $46.666666666666664.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Comcast, which currently sits at a price target of $45.<br />
&#x2A; Maintaining their stance, an analyst from Loop Capital continues to hold a Buy rating for Comcast, targeting a price of $53.<br />
&#x2A; Consistent in their evaluation, an analyst from Macquarie keeps a Neutral rating on Comcast with a target price of $42. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Comcast, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


CMCSA

Check Out What Whales Are Doing With CMCSA

<p>In the latest quarter, 11 analysts provided ratings for Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $80.64, along with a high estimate of $90.00 and a low estimate of $60.00. This upward trend is apparent, with the current average reflecting a 7.91% increase from the previous average price target of $74.73.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738263676_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of Edwards Lifesciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Wolfe Research</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Travis Steed</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$83.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$78.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$68.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$88.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Edwards Lifesciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Edwards Lifesciences compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Edwards Lifesciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into Edwards Lifesciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EW/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Edwards Lifesciences analyst ratings.</strong></a></p>
<h2>About Edwards Lifesciences</h2>
<p>Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.</p>
<h3>Unraveling the Financial Story of Edwards Lifesciences</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Edwards Lifesciences displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>8.93%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Edwards Lifesciences's net margin is impressive, surpassing industry averages. With a net margin of <strong>226.73%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Edwards Lifesciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>36.16%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Edwards Lifesciences's ROA excels beyond industry benchmarks, reaching <strong>26.62%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Edwards Lifesciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.07</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


11 Analysts Have This To Say About Edwards Lifesciences

<p>Financial giants have made a conspicuous bearish move on Datadog. Our analysis of options history for Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) revealed 24 unusual trades.</p>
<p>Delving into the details, we found 29% of traders were bullish, while 58% showed bearish tendencies. Out of all the trades we spotted, 12 were puts, with a value of $846,352, and 12 were calls, valued at $585,217.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $110.0 to $162.5 for Datadog over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Datadog's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Datadog's whale activity within a strike price range from $110.0 to $162.5 in the last 30 days. </p>
<h3>Datadog Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738263674_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DDOG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$0.61</td>
<td>$0.55</td>
<td>$0.57</td>
<td>$110.00</td>
<td>$159.5K</td>
<td>754</td>
<td>2.8K</td>
</tr>
<tr>
<td>DDOG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/31/25</td>
<td>$3.05</td>
<td>$2.83</td>
<td>$3.05</td>
<td>$142.00</td>
<td>$118.3K</td>
<td>4.8K</td>
<td>613</td>
</tr>
<tr>
<td>DDOG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/31/25</td>
<td>$2.5</td>
<td>$2.27</td>
<td>$2.5</td>
<td>$142.00</td>
<td>$104.7K</td>
<td>4.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>DDOG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/31/25</td>
<td>$6.1</td>
<td>$5.85</td>
<td>$6.1</td>
<td>$146.00</td>
<td>$104.3K</td>
<td>853</td>
<td>420</td>
</tr>
<tr>
<td>DDOG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/31/25</td>
<td>$6.0</td>
<td>$5.95</td>
<td>$6.0</td>
<td>$146.00</td>
<td>$85.2K</td>
<td>853</td>
<td>602</td>
</tr>
</tbody>
</table>
</p>
<h3>About Datadog</h3>
<p>Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered via software as a service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of applications throughout their businesses.</p>
<h3>Present Market Standing of Datadog</h3>
<ul>
<li>Currently trading with a volume of 4,059,987, the DDOG's price is down by -3.42%, now at $140.74. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 14 days.</li>
</ul>
<h3>Expert Opinions on Datadog</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $160.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $180.<br />
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on Datadog, which currently sits at a price target of $170.<br />
&#x2A; An analyst from Stifel downgraded its action to Hold with a price target of $140.<br />
&#x2A; Reflecting concerns, an analyst from Morgan Stanley lowers its rating to Equal-Weight with a new price target of $143.<br />
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Datadog with a target price of $170. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Datadog options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


DDOG

Behind the Scenes of Datadog's Latest Options Trends

<p>Throughout the last three months, 6 analysts have evaluated Ashland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $83.0, a high estimate of $93.00, and a low estimate of $68.00. Highlighting a 7.09% decrease, the current average has fallen from the previous average price target of $89.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738263669_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Ashland by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$93.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$84.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$83.00</td>
<td>$92.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ashland. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ashland compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Ashland's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Ashland's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ASH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ashland analyst ratings.</strong></a></p>
<h2>All You Need to Know About Ashland</h2>
<p>Ashland Inc is a world-wide specialty materials company that serves a wide range of industrial markets. The company has a business-centric operating model and is organized into four distinct segments: life sciences, personal care, specialty additives, and intermediates. Key customers for the firm include pharmaceutical companies and manufacturers of personal care products, food and beverages, and nutraceuticals and supplements. The life sciences segment derives maximum revenue. The company generates its sales from North America, Europe, Asia Pacific, and Latin America, and Others.</p>
<h3>Key Indicators: Ashland's Financial Health</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Ashland's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-22.41%</strong>. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.</p>
<p><strong>Net Margin:</strong> Ashland's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-40.74%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Ashland's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-6.04%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-3.03%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Ashland's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.55</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


6 Analysts Assess Ashland: What You Need To Know

<p>In the latest quarter, 5 analysts provided ratings for First Busey (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BUSE#NASDAQ">BUSE</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $29.8, with a high estimate of $34.00 and a low estimate of $25.00. This current average has decreased by 3.87% from the previous average price target of $31.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738263661_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of First Busey among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Rulis</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Damon Delmonte</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Andrew Liesch</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Terry McEvoy</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Damon Delmonte</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to First Busey. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of First Busey compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of First Busey's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into First Busey's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BUSE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on First Busey analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know First Busey Better</h2>
<p>First Busey Corporation is a financial holding company, whose subsidiaries provides retail and commercial banking services, remittance processing, and offers financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech, and Wealth Management. The banking segment generates a vast majority of its revenue.</p>
<h3>First Busey: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining First Busey's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-1.43%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> First Busey's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>24.06%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> First Busey's ROE excels beyond industry benchmarks, reaching <strong>2.02%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.23%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.23</strong>, First Busey adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BUSE

Deep Dive Into First Busey Stock: Analyst Perspectives (5 Ratings)

<p>Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) in the last three months.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Crown Castle and provided 12-month price targets. The average target is $103.5, accompanied by a high estimate of $115.00 and a low estimate of $85.00. A 6.76% drop is evident in the current average compared to the previous average price target of $111.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738263649_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A clear picture of Crown Castle's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$115.00</td>
<td>-</td>
</tr>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$102.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$85.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$104.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Crown Castle. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Crown Castle compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Crown Castle's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Crown Castle's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CCI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Crown Castle analyst ratings.</strong></a></p>
<h2>Get to Know Crown Castle Better</h2>
<p>Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 90,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest us cities. The company has a very concentrated customer base, with about 75% of its revenue coming from the big three us mobile carriers. Crown Castle operates as a real estate investment trust.</p>
<h3>Financial Insights: Crown Castle</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Challenges:</strong> Crown Castle's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately <strong>-0.9%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Crown Castle's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>18.34%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>5.54%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Crown Castle's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.79%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Crown Castle's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>5.6</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where Crown Castle Stands With Analysts

<p>Ratings for SAP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for SAP, revealing an average target of $248.8, a high estimate of $330.00, and a low estimate of $38.00. Surpassing the previous average price target of $232.20, the current average has increased by 7.15%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738263628_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive SAP is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irene Nattel</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$286.00</td>
<td>$283.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$307.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$330.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$283.00</td>
<td>$275.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to SAP. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SAP compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of SAP's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of SAP's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SAP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on SAP analyst ratings.</strong></a></p>
<h2>Get to Know SAP Better</h2>
<p>Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small- to medium-size enterprises.</p>
<h3>Financial Milestones: SAP's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> SAP's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>9.38%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> SAP's net margin excels beyond industry benchmarks, reaching <strong>17.27%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> SAP's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>3.53%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> SAP's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.09%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> SAP's debt-to-equity ratio is below the industry average. With a ratio of <b>0.26</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SAP Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="259" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30132529/Edge-1024x259.png" alt="" class="wp-image-758730" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30132529/Edge-1024x259.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30132529/Edge-300x76.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30132529/Edge-768x194.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30132529/Edge-1536x389.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30132529/Edge.png 1600w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p>With earnings in full swing, Wall Street's stock analysts are releasing upgrades left and right for stocks they think will soar. Above, you can see 10 of yesterday&#8217;s upgrades, including for META, from some of the best analysts in the business — and one you can ignore.</p>
<p>We know, because here at Benzinga, we not only keep track of every rating change and price target analysts set, but also of how accurate each analyst is.</p>
<p>That way you can decide whether these upgrades are worth your time. As you can see above, META, SEIC, and EW were just upgraded from Hold to Buy (or the equivalent) by analysts who are right 70% of the time or more.&nbsp;</p>
<p>That&#8217;s a powerful signal that these stocks deserve a closer look.</p>
<p>Meanwhile, you can also see that stocks such as PCRX, AKRO, and CVLT were handed upgrades by analysts who get it right less than half the time.</p>
<p>You&#8217;d be better off tossing a coin than following that advice.</p>
<p>The Benzinga analyst ratings tracker can show you upgrades and downgrades from many more analysts, including Tuesday&#8217;s upgrade on a little-known stock from an analyst who's right 80% of the time.</p>
<p>To get this information every day, see the rest of the list, and unlock all the major upgrades, downgrades, and changes made by Wall Street's most accurate analysts, <strong><a href="https://www.benzinga.com/premium/ideas/benzinga-edge/?utm_source=WebRD-0131&amp;el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}">get instant access to Edge right here.</a></strong></p>
<p>Image via Shutterstock</p>


Opinion

Meta Beats Earnings But Here's the Other Reason the Stock Rallied

WIIM

RTX shares are trading higher after B of A Securities raised its price target on the stock from $145 to $155.

<p><a href="https://medium.com/avride/avride-and-grubhub-bring-autonomous-delivery-robots-to-u-s-college-campuses-50494150ef16" title="https://medium.com/avride/avride-and-grubhub-bring-autonomous-delivery-robots-to-u-s-college-campuses-50494150ef16">https://medium.com/avride/avride-and-grubhub-bring-autonomous-delivery-robots-to-u-s-college-campuses-50494150ef16</a></p>


NBIS

'Avride and Grubhub Bring Autonomous Delivery Robots to U.S. College Campuses' -Avride Team Medium.com Post

Canadian Pacific Kansas shares are trading higher after Stephens & Co. and RBC Capital raised their respective price targets on the stock.

<p><strong>Howard Hughes Holdings's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HHH#NYSE">HHH</a>) short percent of float has risen 5.57% since its last report. The company recently reported that it has <strong>1.81 million shares sold short</strong>, which is 5.88% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.94 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Howard Hughes Holdings Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738262723_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Howard Hughes Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Howard Hughes Holdings's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Howard Hughes Holdings's peer group average for short interest as a percentage of float is 1.81%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

How Is The Market Feeling About Howard Hughes Holdings?

<p><strong>Rivian Automotive's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NYSE">RIVN</a>) short percent of float has fallen 4.22% since its last report. The company recently reported that it has <strong>143.66 million shares sold short</strong>, which is 19.31% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.32 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Rivian Automotive Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738262718_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Rivian Automotive has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Rivian Automotive's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Rivian Automotive's peer group average for short interest as a percentage of float is 7.00%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


RIVN

(RIVN) - Analyzing Rivian Automotive's Short Interest

<p><strong>MSCI's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) short percent of float has fallen 5.74% since its last report. The company recently reported that it has <strong>773 thousand shares sold short</strong>, which is 1.15% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.9 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>MSCI Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738262713_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for MSCI has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing MSCI's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, MSCI's peer group average for short interest as a percentage of float is 3.26%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


MSCI

Looking Into MSCI's Recent Short Interest

<p>A landmark study published Tuesday in JAMA Network Open found that both recent and lifetime cannabis use may impair brain function during cognitive tasks, particularly those involving working memory.</p>
<p>The <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829657?utm_source=For_The_Media&amp;utm_medium=referral&amp;utm_campaign=ftm_links&amp;utm_term=012825" target="_blank" rel="noreferrer noopener">study</a>, the largest of its kind, examined 1,000 young adults aged 22 to 36 using brain imaging technology. Researchers found that 63% of heavy lifetime cannabis users showed reduced brain activity during a working memory task, while 68% of recent users exhibited a similar decline.</p>
<h1 class="wp-block-heading"><strong>Implications For Memory And Cognitive Performance</strong></h1>
<p>Working memory plays a crucial role in everyday functions, allowing individuals to follow instructions, solve problems and process information efficiently. The decline in brain activity observed in cannabis users correlated with poorer performance on working memory tasks.</p>
<p>&#8220;As cannabis use continues to grow globally, studying its effects on human health has become increasingly important," <a href="https://news.cuanschutz.edu/news-stories/largest-study-ever-done-on-cannabis-and-brain-function-finds-impact-on-working-memory">said</a> lead author <strong>Joshua Gowin</strong>, Ph.D., an assistant professor of radiology at the University of Colorado School of Medicine. "By doing so, we can provide a well-rounded understanding of both the benefits and risks of cannabis use, empowering people to make informed decisions and fully comprehend the potential consequences.&#8221;</p>
<p>A Thursday <a href="https://news.cuanschutz.edu/news-stories/largest-study-ever-done-on-cannabis-and-brain-function-finds-impact-on-working-memory">report</a> by<strong> Julia Milzer</strong> for the Colorado Anschutz Medical Campus noted that the study categorized participants into three groups: heavy users who had consumed cannabis more than 1,000 times in their lifetime, moderate users who had consumed between 10 and 999 times and those who had used marijuana fewer than 10 times, essentially non-users.</p>
<h1 class="wp-block-heading"><strong><strong>Marijuana's Impact On The Brain</strong></strong></h1>
<p>To assess brain function, researchers conducted MRI scans while participants completed seven cognitive tasks. The tests measured working memory, language skills, motor function, emotional processing, decision-making and social cognition. The latter refers to the processes that influence how people respond to social signals.</p>
<p>The most significant impact was observed in the working memory task, where cannabis users exhibited reduced brain activity in key regions, including the dorsolateral prefrontal cortex, dorsomedial prefrontal cortex and anterior insula. These areas are critical for memory, decision-making, attention and emotional regulation.</p>
<p>&#8220;We applied the highest standards to our research, setting rigorous thresholds for statistical significance across all seven cognitive function tests," Gowin said. "While some of the other tasks indicated potential cognitive impairment, only the working memory task showed a statistically significant impact."</p>
<h1 class="wp-block-heading"><strong>Potential For Cognitive Recovery</strong></h1>
<p>While the study suggests that abstaining from cannabis before performing cognitive tasks may help improve function, Gowin cautioned against stopping abruptly.</p>
<p>&#8220;People need to be aware of their relationship with cannabis since stopping cold turkey could disrupt their cognition," he said. "For example, heavy users may need to be more cautious."</p>
<p>Looking ahead, researchers say even larger, long-term studies are needed to determine whether cannabis directly alters brain function, how long these effects last and how different age groups are affected.</p>
<p><strong>Read Also: </strong></p>
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/43278893/how-ozempic-and-legal-weed-are-changing-what-america-eats"><strong>How Ozempic And Legal Weed Are Changing What America Eats</strong></a></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Cannabis

Education

Health Care

Cannabis Use Reduces Brain Activity In Cognitive Tasks, Largest Study To Date Finds

Oppenheimer notes that Veru (VERU) presented a meta-analysis of results from four prior placebo-controlled Phase 2 and 3 clinical studies of enobos...

Oppenheimer would be buyers of Veru ahead of January's top line readout

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Veru (VERU – Research Report), Ascendis Pharma (ASND...

Analysts Are Bullish on These Healthcare Stocks: Veru (VERU), Ascendis Pharma (ASND)

Veru (VERU) has sold its FC2 Female Condom business to clients managed by Riva Ridge Capital Management as well as other co-investors, for $18M, su...

Veru sells FC2 Female Condom business for $18M

Veru surges as it sells FC2 female condom business to private investors

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Corvus Pharmaceuticals (CRVS – Research Report) and ...

Analysts Offer Insights on Healthcare Companies: Corvus Pharmaceuticals (CRVS) and Veru (VERU)

Veru ( ($VERU) ) just unveiled an update. Veru Inc. announced the sale of its FC2 Female Condom business to Clear Future, Inc. for $18 million. Thi...

Veru Inc. Sells FC2 Business to Focus on Biopharma

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Argenx Se (ARGX – Research Report) and Veru (VERU – ...

Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Veru (VERU)

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Veru down 46% despite data for drug preserving lean body mass in Wegovy users

William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target remains th...

Veru Inc.'s Promising Phase IIb Results Suggest Investment Opportunity with Enobosarm's Weight Management Potential

ARGX

ASND

CHRO

CRVS

DRMA

DWTX

GNLX

NTRB

VERU

Press Releases

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024

Biotech

General

Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

Veru to Present at the 2024 Cantor Global Healthcare Conference

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

CMRX

NNVC

SIGA

BellRing Brands

Coty

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

e.l.f. Beauty

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Herbalife

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Honest Co

Interparfums

Kenvue

Lifevantage

Medifast

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Nu Skin Enterprises

Olaplex Hldgs

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Enter

The Beauty Health Company - Class A Common Stock

Beauty Health

United-Guardian

Unilever

Usana Health Sciences

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

Comments

Veru

ニュース

最新ニュース Veru (NASDAQ:VERU) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル